Skip to main content

Catalyst Calendar

Mon, Aug 24, 2026

1 updates

7:30 PM

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Trial Start • Phase 3Trial initiation Tue, Aug 25, 2026astellas.com

Thu, Aug 6, 2026

1 updates

10:30 PM

Submission of New Drug Application for Fezolinetant in Japan for the Treatment of Vasomotor Symptoms Associated with Menopause

astellas.com

Wed, Aug 5, 2026

1 updates

2:30 AM

Q1/FY2026 Financial results

astellas.com

Sun, Jul 12, 2026

1 updates

7:30 PM

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

astellas.com

Mon, Jul 6, 2026

1 updates

10:30 PM

China’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancer

astellas.com

Tue, Jun 23, 2026

1 updates

7:30 PM

European Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancer

astellas.com

Fri, May 29, 2026

1 updates

3:00 AM

Notice Regarding the Resignation of an Outside Director and Partial Withdrawal of Matters to be Resolved at the 21st Term Annual Shareholders Meeting

astellas.com

Thu, May 28, 2026

1 updates

11:00 PM

Astellas’ View on ISS Voting Recommendations

astellas.com